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Despite a significant increase of the number of radical prostatectomies (RPs) to treat organ-confined prostate cancer, there is very
limited documentation of its oncological outcome in the UK. Pathological stage distribution and changes of outcome have not been
audited on a consistent basis. We present the results of a multicentre review of postoperative predictive variables and prostatic-
specific antigen (PSA) recurrence after RP for clinically organ-confined disease. In all, 854 patient’s notes were audited for staging
parameters and follow-up data obtained. Patients with neoadjuvant and adjuvant treatment as well as patients with incomplete data
and follow-up were excluded. Median follow-up was 52 months for the remaining 705 patients. The median PSA was 10ngml
 1.A
large migration towards lower PSA and stage was seen. This translated into improved PSA survival rates. Overall Kaplan–Meier PSA
recurrence-free survival probability at 1, 3, 5 and 8 years was 0.83, 0.69, 0.60 and 0.48, respectively. The 5-year PSA recurrence-free
survival probability for PSA ranges o4, 4.1–10, 10.1–20 and 420ngml
 1 was 0.82, 0.73, 0.59 and 0.20, respectively (log rank,
Po0.0001). PSA recurrence-free survival probabilities for pathological Gleason grade 2–4, 5 and 6, 7 and 8–10 at 5 years were 0.84,
0.66, 0.55 and 0.21, respectively (log rank, Po0.0001). Similarly, 5-year PSA recurrence-free survival probabilities for pathological
stages T2a, T2b, T3a, T3b and T4 were 0.82, 0.78, 0.48, 0.23 and 0.12, respectively (log rank, P¼0.0012). Oncological outcome after
RP has improved over time in the UK. PSA recurrence-free survival estimates are less optimistic compared to quoted survival figures
in the literature. Survival figures based on pathological stage and Gleason grade may serve to counsel patients postoperatively and to
stratify patients better for adjuvant treatment.
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Recurrence of prostate cancer is of concern for men undergoing
radical prostatectomy (RP) with curative intent. Nearly 30% of
patients will develop prostatic specific antigen (PSA) recurrence.
Patients having undergone RP and treating surgeons need to
know the risk of PSA recurrence following RP. However,
figures for PSA recurrence following RP in the UK are sparse
(Feneley et al, 1996; Doherty et al, 2000; Bott and Kirby, 2002).
This and a trend towards lower preoperative PSA values and
stage over the last 10 years suggests there is a continuing but
hitherto unmet need for reliable outcome data from large
treatment series to document cancer control rates following
RP with curative intend in the UK.
Many variables have been shown to be associated with the
probability of PSA recurrence following RP. It is not entirely
certain as to which variable indicates tumour recurrence for the
individual patient. These variables may also change over time and
may be of varying importance for different patient populations.
Contemporary updates of variables predicting outcome will
provide more accurate information for prognostic models and
may aid clinical decision-making. In particular, the effect of a
downward stage migration for prostate cancer may have an impact
on PSA recurrence following RP. This stage migration is usually
seen in regions with a high penetrance of PSA testing. It is
estimated that only 3.5% of all men are tested annually with a
serum PSA in the UK compared to 20% in the US in 1999 (Melia
and Moss, 2001; Oliver et al, 2003).
Despite the absence of reliable evidence of its effectiveness, RP
has become an increasingly popular treatment for selected patients
with organ-confined prostate cancer in England over the last
decade (Oliver et al, 2003). Holmberg et al (2002) showed in the
only adequately powered randomised trial to date that prostate
cancer-specific death is reduced by 50%, but there was no
significant difference between surgery and watchful waiting
in terms of overall survival (Holmberg et al, 2002). There is
as yet no confirmed influence on the survival of men with screen-
detected disease.
We retrospectively reviewed a large series of men who under-
went RP in the South of England to document contemporary PSA
recurrence-free survival probabilities and identify pathological
factors of PSA recurrence.
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lMATERIALS AND METHODS
In all, 854 patient’s notes from five Urology units (two academic
units and three District General Hospitals) were audited for
preoperative staging parameters and follow-up data obtained. All
units had at least a yearly throughput of 20 procedures. Data were
collected retrospectively from 1989 to 1999. From 2000 onwards
databases were continuously updated. Most patients underwent
radical retropubic prostatectomy apart from 150 patients who
underwent radical perineal prostatectomy. Patients with neoadju-
vant treatment were included in the analysis of stage migration.
Patients with neoadjuvant (84 patients) and adjuvant treatment
prior to PSA recurrence (36 patients) as well as patients with
incomplete data and follow-up of o12 months (29 patients) were
excluded from survival analysis. Cox’s proportional-hazards
regression was used to identify factors associated with biochemical
recurrence in the first 5 years following RP. Patients with positive
lymph nodes were included if they underwent synchronous RP in
the analysis of overall survival. However, since 150 patients
underwent radical perineal prostatectomy and only 10 of those
patients had synchronous lymphadenectomy, lymph node-positive
patients were excluded from the multivariate analysis. Probability
estimates of recurrence-free survival were calculated with the
Kaplan–Meier method for all significant predictors. Continuity
corrected w
2 test and Wilcoxon’s test were used to compare factors
reflecting patient selection. Log rank and Wilcoxon’s test were
used to compare Kaplan–Meier survival curves and survival
probabilities. The preoperative PSA was recorded prior to any
intervention, that is, digital rectal examination, biopsy or TURP.
Biochemical recurrence was defined as at least two consecutive
elevations above a PSA of 0.2ngml
 1. A positive surgical margin
was defined as prostatic adenocarcinoma at the inked margin of
the pathological specimen regardless of the location of the margin
and the extent of margin and carcinoma involved. This was
necessary because histopathological reporting practice varied
widely. Staging followed the 1997 TNM classification.
RESULTS
Median prebiopsy PSA was 10.0ngml
 1 (mean 12.3ngml
 1)
(Table 1). Pre- and postoperative descriptive data of the entire
cohort of 747 patients after exclusion of 107 patients with missing
data of interest for this analysis are shown in Table 1. A median
age of 64 years was recorded. There was a statistically significant
trend over time towards lower preoperative PSA (w
2¼78.62,
Po0.0001), improved pathological stage (w
2¼12.64, P¼0.0132)
and improved local excision rates (w
2¼10.65, P¼0.0308).
Surgically organ-confined disease was found in 39% in 1988–
1994 and 61% in 2001–2002. A positive surgical margin was
observed in 46% in 1988–1994 and 30% in 2001–2002.
The median follow-up was 52 months for all the 705 patients
included in the survival analysis.
Overall Kaplan–Meier PSA recurrence-free survival probabil-
ities at 1, 3, 5 and 8 years were 0.83 (CI 0.80–0.86), 0.69 (CI 0.64–
0.74), 0.60 (CI 0.54–0.66) and 0.48 (CI 0.37–0.59), respectively.
The median overall survival time was reached at 9.07 (CI 5.99–
12.14) years.
The 5-year PSA recurrence-free survival probabilities increased
significantly over time and were 0.49 (CI 0.40–0.58), 0.63
(CI 0.53–0.73) and 0.79 (CI 0.71–0.87) for the years 1988–1994,
1995–1996 and 1997–1998, respectively (log rank, Po0.0001)
(Figure 1). Survival probabilities could not be calculated for
1999–2002 because follow-up was too short to permit comparison
over time.
Cox’s (proportional-hazards) regression identified preoperative
PSA (Po0.0001), pathological Gleason grade (P¼0.0178), patho-
logical stage (o0.0001) and margin status (o0.0001) as significant
predictors of PSA recurrence for the 671 patients without lymph
node metastases and after other exclusions. Kaplan–Meier survival
curves for PSA, pathological stage, pathological Gleason grade and
surgical margin status are illustrated in Figures 2–5. The 5-year
PSA recurrence-free survival probabilities and median survival
times for all significant predictive variables (PSA, pathological
stage, pathological Gleason grade and margin status) are shown in
Table 2.
DISCUSSION
Despite a significant increase of the number of RPs to treat organ-
confined prostate cancer, there is very limited documentation of its
Table 1 Pre- and post-operative descriptive statistics
Frequency (n) Relative %
PSA (ngml
 1)
a
o4 63 8.6
4–10 320 43.8
10.1–20 249 34.1
420 99 13.5
Biopsy Gleason grade
a
2–4 135 18.9
5, 6 436 61.3
7 102 14.3
8–10 38 5.3
Clinical stage
a
T1a/b 38 5.6
T1c 287 41.9
T2a 257 37.6
T2b 102 14.9
Frequency (n)n g m l
 1
PSA (all patients)
a
Median 731 10.0
Mean 731 12.3
PSA (pts without recurrence)
Median 551 9
Mean 551 10
PSA (pts with recurrence)
Median 180 14
Mean 180 16.6
Frequency (n) Relative %
Pathological stage
a
T0 6 0.8
T2a 347 47.1
T2b 55 7.5
T3a 267 36.3
T3b 40 5.4
T4 21 2.9
Pathological Gleason grade
a
2–4 65 8.9
5, 6 402 55.1
7 189 25.9
8–10 74 10.1
Lymph node status
a
Negative 667 95.1
Positive 34 4.9
Surgical margin status
a
Negative 465 63.2
Positive 271 36.8
PSA¼prostatic-specific antigen.
aPatients with missing data excluded.
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loncological outcome in the UK. Pathological stage distribution and
changes of outcome have not been audited on a consistent basis.
We present the results of a multicentre review of postoperative
predictive variables and PSA recurrence after RP for clinically
organ-confined disease.
Particular attention was paid to include all patients who had a
RP regardless of surgical margin or lymph node status. However,
the majority of patients who underwent radical perineal prosta-
tectomy did so without pelvic lymphadenectomy. All patients with
positive lymph nodes were therefore excluded from the multi-
variate analysis, but were included in the calculation of overall
survival probabilities. True outcome figures based on preope-
rative parameters can only be calculated if an intention to treat
analysis is used.
Traditionally, urologists in England have been slow to take up
this procedure to cure prostate cancer because there was a distinct
lack of reliable data to support any specific recommendation for
the treatment of early prostate cancer. Recently, Oliver et al (2003)
demonstrated a nearly 20-fold increase of the number of RPs
performed annually between 1991 and 1999 in England. They
stated that these developments occurred in the absence of robust
information about the effectiveness of RP. There is now some
limited evidence that RP can reduce death from prostate cancer
(Holmberg et al, 2002).
We have shown that a significant stage migration has occurred
in England with the result of large improvements in 5-year PSA
recurrence-free survival after RP (Figure 1). Stage migration
towards lower clinical and pathological stage has been demon-
strated in other countries (Litwiller et al, 1995; Moul et al, 2002)
and likewise this has led to an improvement in overall PSA
recurrence-free survival rates (Moul et al, 2002; Ung et al, 2002;
Freedland et al, 2003). The changes of pathological stage
proportions have an impact on overall PSA recurrence-free
survival. However, PSA recurrence-free survival rates for the
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Figure 1 PSA recurrence-free survival curves by year of operation (log
rank, P¼0.0006).
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Figure 2 PSA recurrence-free survival curves by preoperative PSA (log
rank, Po0.0001).
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Figure 3 PSA recurrence-free survival curves by pathological stage (log
rank, Po0.0001).
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Figure 4 PSA recurrence-free survival curves by pathological Gleason
grade (log rank, Po0.0001).
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Figure 5 PSA recurrence-free survival curves by status of resection
margin (log rank, Po0.0001).
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lseparate stages and grades should only be affected marginally.
Hence, the calculated 5-year PSA recurrence-free survival prob-
abilities for stages, PSA ranges, Gleason grade groups and margins
status should be reliable and useful reference data despite the
observed stage migration.
It is encouraging to see urologists in England have largely
moved away from selecting patients with a preoperative PSA of
420ngml
 1 for RP with their associated high rates of nonorgan-
confined disease (D’Amico et al, 2002). Rates of patients with a
preoperative PSA 420ngml
 1 have dropped from 38% in 1988–
1994 to 7% in 2001–2002. PSA recurrence rates after RP for patients
with a preoperative PSA of 420ngml
 1 c a nb ea sh i g ha s4 6 – 5 9 %
(Hull et al, 2002), being 80% in this study. The median time to PSA
recurrence for this patient group is only 2.57 years (Table 2). Even
patients with a preoperative PSA of 10–20ngml
 1 only have a
median time to PSA recurrence of 7.21 years and the PSA
recurrence-free survival at 5 years is 59%. This is in contrast to
published figures of 65–72% for PSA recurrence-free survival rates
at 5 years (Hull et al, 2002). One has to question the use of a
procedure with curative intent under these circumstances and
preoperative selection criteria may have to be tightened up even
further. If a patient with a PSA 420ngml
 1 is selected for RP, he
should certainly be counselled appropriately for an 80% probability
of recurrence and the anticipated need for further treatment.
Although positive surgical margin rates have improved, a rate
of 30% is still higher than the 14–19% reported in most other
RP series (Stamey et al, 1998; Hull et al, 2002; Han et al,
2003). Although most authors have reported a reduction of the
positive surgical margin rate as a reflection of improved case
selection over time (Stamey et al, 1998; Han et al, 2003),
others could not demonstrate this (Freedland et al, 2003). It may
be that English urologists still operate on larger volume cancers
because screening healthy asymptomatic men (and finding
asymptomatic, low volume cancers) is currently discouraged by
the Department of Health. Certainly, all surgeons involved in this
audit have a high annual throughput of at least 20 procedures,
which makes it less likely that this figure is due to technical
shortfalls during the learning curve. However, surgeon volume
does have an impact on outcome and is inversely related to
in-hospital complications and length of stay in men under-
going RP, illustrating the potential influence of a learning curve
(Hu et al, 2003). Finally, we used a wide definition of positive
surgical margins in order to accommodate the variable reporting
style of the involved histopathologists who were not always
specialised uropathologists. This may have slightly inflated our
positive surgical margin rates. It is of paramount importance to
reduce the positive surgical margin rate with its associated
high PSA recurrence rate (Table 2). This may mean that
there should only be an attempt to spare the neurovascular
bundles for highly selected cases.
Multivariate analysis identified preoperative PSA (Po0.0001),
pathological Gleason grade (P¼0.0178), pathological stage
(o0.0001) and margin status (o0.0001) as highly significant
predictors of PSA recurrence as already known (Hull et al, 2002).
PSA recurrence-free survival figures are presented for these
predictors. The PSA recurrence rates are in general higher for
higher pathological stages and grades in comparison to the
literature (Han et al, 2001, 2003; Hull et al, 2002). It is surprising to
see pathological Gleason grade as the least significant predictor of
PSA recurrence. There is only a minimal difference of PSA
recurrence-free survival rates between Gleason grade 5–6 and 7 at
8 years. This suggests that many Gleason grade 7 cancers have
probably been undergraded as a result of the varying reporting
practice.
Overall PSA recurrence-free survival estimates are less optimis-
tic compared to frequently quoted figures (Stamey et al, 1998;
Walsh, 2000; Han et al, 2001, 2003; Hull et al, 2002) and seem to
show a more realistic picture following surgery for organ-confined
prostate cancer in the UK. Generally, a figure of 78–84% is quoted
for overall PSA recurrence-free survival at 5 years compared to
60% in our study (Hull et al, 2002; Han et al, 2003). The 5-year PSA
recurrence-free survival rates improved over time from 49% before
1994 to 79% in 1997–1998 (Figure 1). This is indeed an acceptable
figure and corresponds well with other published PSA recurrence
figures (Stamey et al, 1998), albeit the best series do report 5-year
PSA recurrence-free survival rates of 480% (Han et al, 2003). It
appears that the combination of improved case selection and
increasing use of PSA testing lead to an improvement of PSA
recurrence-free survival after RP for organ-confined prostate
cancer in the UK.
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